BioLargo, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $1.1M | $616.0K | $1.1M | $2.8M | $3.3M | $3.7M | $4.4M |
| Cost of Revenue | $573.0K | $657.0K | $491.0K | $731.0K | $1.4M | $1.8M | $1.9M | $2.6M |
| Gross Profit | $675.0K | $458.0K | $125.0K | $372.0K | $1.4M | $1.5M | $1.7M | $1.7M |
| Gross Margin | 54.1% | 41.1% | 20.3% | 33.7% | 51.2% | 45.5% | 47.8% | 39.6% |
| Operating Expenses | ||||||||
| Research & Development | $1.1M | $907.0K | $652.0K | $615.0K | $535.0K | $791.0K | $785.0K | $690.0K |
| SG&A Expense | $3.3M | $2.8M | $3.5M | $3.1M | $2.7M | $2.5M | $2.6M | $2.1M |
| Operating Income | $-3.7M | $-3.2M | $-4.0M | $-7.2M | $-1.8M | $-1.9M | $-1.6M | $-1.1M |
| Operating Margin | -298.7% | -287.4% | -651.1% | -651.0% | -64.9% | -57.0% | -44.3% | -24.4% |
| Interest Expense | $285.0K | $188.0K | $188.0K | $144.0K | $115.0K | $93.0K | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-4.0M | $-3.4M | $-4.1M | $-7.2M | $-1.9M | $-1.9M | $-1.7M | $-1.1M |
| Net Margin | -320.5% | -305.4% | -672.4% | -656.8% | -67.8% | -58.8% | -47.4% | -24.4% |
| EPS (Basic) | $-0.01 | $-0.01 | $-0.02 | $-0.02 | $0.00 | $0.00 | $-0.01 | $0.00 |
| EPS (Diluted) | — | — | — | — | — | — | — | — |
| Shares Outstanding (Basic) | 321.0M | 318.7M | 307.0M | 309.0M | 303.2M | 301.3M | 298.1M | 300.5M |
| Shares Outstanding (Diluted) | 321.0M | 318.7M | 307.0M | 309.0M | 303.2M | 301.3M | 298.1M | 300.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |